Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The SARS-CoV-2 membrane (M) protein is a critical structural component that serves as a scaffold for viral assembly and budding. As the most abundant protein in the viral envelope, M mediates interactions with spike (S), envelope (E), and nucleocapsid (N) proteins, organizing their localization to sites of viral assembly. The M protein contains multiple T cell epitope regions that are recognized by CD4+ and CD8+ T cells following natural infection or vaccination. While specific M protein-derived epitopes (such as nucleocapsid protein cross-reactive regions) can generate robust T cell responses, the M protein itself is not a direct pharmaceutical drug target. Rather, M protein epitopes are of significant interest for rational vaccine design, as they represent conserved immunodominant regions less susceptible to viral mutations compared to spike protein epitopes, potentially providing durable cross-protection against SARS-CoV-2 variants.
N/A for epitopes (they are vaccine immunogens, not drug targets)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SARS-CoV-2 membrane protein (M protein) (M protein).